DNL151

DRUG2 trials

Sponsors

Biogen, Denali Therapeutics Inc.

Conditions

Healthy VolunteersParkinson's Disease

Phase 1

Study to Evaluate DNL151 in Subjects With Parkinson's Disease

CompletedNCT04056689

BiogenParkinson's Disease

Start: 2019-07-23End: 2020-12-02Updated: 2023-04-18

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Healthy Volunteers

CompletedNCT04557800

Denali Therapeutics Inc.Healthy Volunteers

Start: 2017-11-16End: 2021-02-19Updated: 2022-03-07

Related Papers

Targeting protein kinases in Parkinson's disease: the emerging role of phytoconstituents.

2025-07-18

Genetic Testing for <scp><i>GBA</i></scp> and <scp><i>LRRK2</i></scp> Mutations: Is it Time for Routine Use?

Movement Disorders Clinical Practice2022-11-112 citations

LIPAD (LRRK2/Luebeck International Parkinson's Disease) Study Protocol: Deep Phenotyping of an International Genetic Cohort

Frontiers in Neurology2021-08-098 citations